CLOUDBREAK PHARMA INC.

拨康视云制药有限公司

02592.HK

Clinical-stage biotechnology company developing novel ophthalmic therapies for eye diseases, with in-house drug discovery and development targeting global unmet needs, particularly conditions like pterygium and vascularised pinguecula lacking treatment options.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Chapter 18A biotech